Frankfurt - Delayed Quote EUR

Inovio Pharmaceuticals, Inc. (GBM.F)

1.9400
-0.0800
(-3.96%)
At close: June 9 at 8:08:17 AM GMT+2
Loading Chart for GBM.F
  • Previous Close 2.0200
  • Open 1.9400
  • Bid 1.9100 x --
  • Ask 1.9600 x --
  • Day's Range 1.9400 - 1.9400
  • 52 Week Range 1.3000 - 10.4800
  • Volume 20
  • Avg. Volume 126
  • Market Cap (intraday) 71.148M
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7500
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

www.inovio.com

134

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GBM.F

View More

Performance Overview: GBM.F

Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GBM.F
8.99%
S&P 500 (^GSPC)
2.11%

1-Year Return

GBM.F
78.56%
S&P 500 (^GSPC)
12.32%

3-Year Return

GBM.F
90.23%
S&P 500 (^GSPC)
49.48%

5-Year Return

GBM.F
98.59%
S&P 500 (^GSPC)
87.26%

Compare To: GBM.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GBM.F

View More

Valuation Measures

Annual
As of 6/6/2025
  • Market Cap

    72.69M

  • Enterprise Value

    22.84M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    253.26

  • Price/Book (mrq)

    1.66

  • Enterprise Value/Revenue

    92.40

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -61.21%

  • Return on Equity (ttm)

    -132.44%

  • Revenue (ttm)

    283.1k

  • Net Income Avi to Common (ttm)

    -96.48M

  • Diluted EPS (ttm)

    -2.7500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    68.36M

  • Total Debt/Equity (mrq)

    21.99%

  • Levered Free Cash Flow (ttm)

    -52.11M

Research Analysis: GBM.F

View More

Company Insights: GBM.F

Research Reports: GBM.F

View More